JINAN GREAT CHEMICAL INDUSTRY CO., LTD

TEL: +86-531-58668191

FAX:+86-531-69987825

MOB: +8618954127179

E-mail: wendy@chemgreat.com

ADD: Environmental Science and Technology Parks, Jinan,Shandong Province, China

Abiraterone Acetate CAS 154229-18-2;Abiraterone Acetate;CB 7630

Abiraterone Acetate CAS 154229-18-2;Abiraterone Acetate;CB 7630

Jinan Great Chemical Industry Co., Ltd is a professional Abiraterone acetate manufacturer and supplier in China. We guarantee to supply high quality Abiraterone acetate with competitive price. If you are in need of Abiraterone acetate, please don’t hesitate to contact sale001@chemgreat.com.

Description

Description

Abiraterone acetate is a CYP17 inhibitor suitable for use in combination with prednisone for the treatment of patients with previously transplanted castration-refractory prostate cancer with docetaxel [docetaxel].

Parameter

Chemical name

Abiraterone acetate

Molecular Structure

图片9.jpg

Molecular Formular

C26H33NO2

Molecular Weight

391.5457

Cas No.

154229-18-2

Appearance

White or off-white powder

Purity

99%

Melting point

127-130°C

Boiling point

506.7°C at 760 mmHg

Package

Foil bag

Storage Conditions

-20°C Freezer

Application

Research reagents, widely used in molecular biology, pharmacology and other scientific research

Warnings and precautions

(1) Mineralocorticoid excess: Patients with a history of cardiovascular disease use ZYTIGA with caution. The safety of ZYTIGA in patients with ejection fraction LVEF < 50% or NYHA class III or IV heart failure has not been determined. Control high blood pressure and correct hypokalemia before treatment. Check blood pressure, serum potassium and fluid retention symptoms at least once a month.

(2) Adrenal insufficiency: Monitor symptoms and signs of adrenal insufficiency. It may be appropriate to increase the corticosteroid dose before, during and after an emergency.

(3) Hepatotoxicity: An increase in liver enzymes has led to drug interruption, dose adjustment and/or termination. Monitor liver function and, if recommended, adjust, discontinue or discontinue ZYTIGA dosing.

(4) Food effects: ZYTIGA must be taken on an empty stomach. When exposed to food with abiraterone acetate abiraterone, the exposure (area under the curve) increased by a factor of 10.

Adverse reactions

The most common adverse reactions (≥ 5%) are joint swelling or discomfort, hypokalemia, edema, muscle discomfort, hot flashes, diarrhea, urinary tract infections, cough, high blood pressure, arrhythmia, frequent urination, nocturia, indigestion, And upper respiratory tract infection.

Related Products

Feedback